Cost-effectiveness of natalizumab in patients with Crohn's disease who have failed Anti-TNFα therapy

被引：0
|
作者：
Sands, Bruce
Wolf, Douglas
Panjabi, Sumeet
Niecko, Timothy
Hass, Steven
Lacey, Loretto
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Atlanta Gastroenterol Associates, Atlanta, GA USA
[4] Elan Pharmaceut Inc, San Francisco, CA USA
[5] LLC, Niecko Hlth Econ, Escondido, CA USA
[6] Elan Pharmaceut Ltd, Pharmacoecon, Dublin, Ireland
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
10.14309/00000434-200809001-01025
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1025
引用
收藏
页码：S401 / S402
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Sands, Bruce E.
    Wolf, Douglas C.
    Panjabi, Sumeet
    Niecko, Timothy
    Hass, Steven
    Lacey, Loretto
    Spencer, Mike
    GASTROENTEROLOGY, 2008, 134 (04) : A638 - A638
  • [2] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Panjabi, S.
    Niecko, T.
    Hass, S. L.
    Lacey, L.
    Spencer, M. D.
    VALUE IN HEALTH, 2008, 11 (03) : A85 - A85
  • [3] Cost-effectiveness of Natalizurnab in patients with Crohn's Disease who have failed TNF-alpha inhibitor therapy
    Wolf, D.
    Sands, B.
    Panjabi, S.
    Niecko, T.
    Hass, S.
    Lacey, L.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S38 - S38
  • [4] Cost-Effectiveness of Third-line Anti-TNF Therapy Compared to Natalizumab in Patients With Moderate-to-Severe Crohn's Disease With Two Prior Anti-TNF Failures
    Ananthakrishnan, Ashwin N.
    Hur, Chin
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2011, 140 (05) : S780 - S780
  • [5] Natalizumab induces sustained response and remission in the absence of concomitant immunosuppressants in patients with Crohn's disease who failed prior Anti-TNFα therapy
    Lashner, B.
    Colombel, J. F.
    Enns, R.
    Feagan, B. G.
    Fedorak, R. N.
    Hanauer, S. B.
    Lawrance, I. C.
    Panaccione, R.
    Present, D.
    Ridgeerts, P.
    Sandborn, W. J.
    Sanders, M.
    Schreiber, S.
    Spehlmann, M. E.
    Talassay, Z.
    van Deventer, S.
    Volfova, M.
    Wolf, D. C.
    Targan, S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S493 - S493
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY
    Wilson, M.
    Lucas, A.
    VALUE IN HEALTH, 2018, 21 : S145 - S145
  • [7] Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent
    del Carmen R-Grau, Maria
    Chaparro, Maria
    Mesonero, Francisco
    Barreiro-de Acosta, Manuel
    Castro, Luisa
    Castro, Manuel
    Domenech, Eugeni
    Mancenido, Noemi
    Lazaro Perez-Calle, Jose
    Taxonera, Carlos
    Barrio, Jesus
    De Francisco, Ruth
    Fernandez-Salgado, Estela
    Luzon, Lara
    Merino, Olga
    Oltra, Lorena
    Saro, Cristina
    Bermejo, Fernando
    Garcia-Sanchez, Valle
    Ginard, Daniel
    Gutierrez, Ana
    Vera, Isabel
    Anton, Rosario
    Ber, Yolanda
    Calvet, Xavier
    Gisbert, Javier P.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 613 - 619
  • [8] Anti-TNF therapy and Crohn's disease
    Peyrin-Biroulet, L.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2008, 32 (05): : 478 - 481
  • [9] Anti-TNF Therapy in Crohn's Disease
    Adegbola, Samuel O.
    Sahnan, Kapil
    Warusavitarne, Janindra
    Hart, Ailsa
    Tozer, Philip
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [10] Another anti-TNF therapy for patients with Crohn's disease
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (03) : 425 - 427
12345